[go: up one dir, main page]

MA31067B1 - COMPOUNDS AND METHODS FOR INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS. - Google Patents

COMPOUNDS AND METHODS FOR INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS.

Info

Publication number
MA31067B1
MA31067B1 MA31972A MA31972A MA31067B1 MA 31067 B1 MA31067 B1 MA 31067B1 MA 31972 A MA31972 A MA 31972A MA 31972 A MA31972 A MA 31972A MA 31067 B1 MA31067 B1 MA 31067B1
Authority
MA
Morocco
Prior art keywords
compounds
methods
binding partners
bcl proteins
inhibiting interaction
Prior art date
Application number
MA31972A
Other languages
Arabic (ar)
French (fr)
Inventor
Alfredo C Castro
Edward B Holson
Brian T Hopkins
Nii O Koney
Daniel A Snyder
Thomas T Tibbitts
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Publication of MA31067B1 publication Critical patent/MA31067B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un aspect de la présente invention concerne des composés hétérocycliques qui lient les protéines bcl et inhibent la fonction bci. Un autre aspect de la présente invention concerne des compositions comprenant un composé hétérocyclique selon l'invention. La présente invention concerne des procédés de traitement et de modulation des troubles associés à l'hyperprolifération, tels que le cancer.One aspect of the present invention relates to heterocyclic compounds which bind bcl proteins and inhibit bci function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound according to the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

MA31972A 2006-11-15 2009-06-10 COMPOUNDS AND METHODS FOR INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS. MA31067B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/600,332 US7842815B2 (en) 2004-06-17 2006-11-15 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
PCT/US2007/023941 WO2008060569A1 (en) 2006-11-15 2007-11-14 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Publications (1)

Publication Number Publication Date
MA31067B1 true MA31067B1 (en) 2010-01-04

Family

ID=39064388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31972A MA31067B1 (en) 2006-11-15 2009-06-10 COMPOUNDS AND METHODS FOR INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS.

Country Status (20)

Country Link
US (2) US7842815B2 (en)
EP (1) EP2094673B1 (en)
JP (2) JP2010510214A (en)
KR (1) KR101530721B1 (en)
CN (1) CN101583606B (en)
AU (1) AU2007319848B2 (en)
BR (1) BRPI0718606A2 (en)
CA (1) CA2669596C (en)
EC (1) ECSP099398A (en)
ES (1) ES2537762T3 (en)
GT (1) GT200900123A (en)
IL (1) IL198597A (en)
MA (1) MA31067B1 (en)
MX (1) MX2009005184A (en)
MY (1) MY156754A (en)
NO (1) NO20092306L (en)
NZ (1) NZ577243A (en)
RU (1) RU2449996C2 (en)
TN (1) TN2009000182A1 (en)
WO (1) WO2008060569A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095063A1 (en) 2007-01-31 2008-08-07 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US20090275519A1 (en) 2008-02-08 2009-11-05 Aileron Therapeutics, Inc. Therapeutic peptidomimetic macrocycles
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
KR20140100937A (en) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
US8945853B2 (en) 2012-02-06 2015-02-03 Discoverx Corporation Detection of intracellular binding events by measuring protein abundance
JP6450192B2 (en) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド Triazole-bridged and thioether-bridged peptidomimetic macrocycles
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN103656642A (en) * 2012-08-31 2014-03-26 中国科学院上海生命科学研究院 Method and reagent for preventing and treating colorectal cancer
US20160068463A1 (en) 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CN112274641A (en) 2014-01-28 2021-01-29 巴克老龄化研究所 Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN108368161A (en) 2015-09-10 2018-08-03 艾瑞朗医疗公司 Peptidomimetic macrocyclic compound as MCL-1 conditioning agents
KR102275758B1 (en) 2016-03-28 2021-07-12 프레시지 바이오싸이언시스, 인크. Pharmaceutical Combinations for the Treatment of Cancer
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN110831946B (en) * 2017-04-05 2022-06-21 哈佛大学的校长及成员们 Macrocyclic compounds and their uses
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
WO2021233948A1 (en) 2020-05-19 2021-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat a pathogen lung infection
EP4175644A1 (en) 2020-07-06 2023-05-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
WO2025087879A2 (en) 2023-10-23 2025-05-01 Institut National de la Santé et de la Recherche Médicale Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS55133364A (en) 1979-04-03 1980-10-17 Mitsubishi Petrochem Co Ltd Preparation of isoxazolidine derivative
DE3643012A1 (en) 1986-12-17 1988-06-30 Hoechst Ag 2,3-DISUBSTITUTED ISOXAZOLIDINE, METHOD FOR THE PRODUCTION THEREOF, THE CONTAINERS THEREOF AND THEIR USE
EP0527736B1 (en) 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
US5294617A (en) * 1993-04-23 1994-03-15 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
EP0623615B1 (en) * 1993-05-01 1999-06-30 MERCK PATENT GmbH Substituted 1-phenyl-oxazolidin-2-one derivatives, their preparation and their use as adhesion-receptor antagonists
WO1995014683A1 (en) 1993-11-24 1995-06-01 The Du Pont Merck Pharmaceutical Company Novel isoxazoline and isoxazole fibrinogen receptor antagonists
US5869511A (en) 1994-03-09 1999-02-09 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
US5514505A (en) * 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
DE19539638A1 (en) 1995-10-25 1997-04-30 Hoechst Ag The use of isoxazole and crotonic acid amide derivatives for the treatment of cancer
US6221865B1 (en) * 1995-11-06 2001-04-24 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
ES2189968T3 (en) 1996-08-16 2003-07-16 Bristol Myers Squibb Pharma Co Amidinophenyl-pyrrolidines, -pyrrolines, e -isoxazolidines and derivatives thereof.
WO1998016830A2 (en) 1996-10-16 1998-04-23 The President And Fellows Of Harvard College Droplet assay system
AU7371998A (en) 1997-05-07 1998-11-27 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
WO2001016115A1 (en) 1999-09-01 2001-03-08 Chemrx Advanced Technologies, Inc. Process for synthesizing isoxazolidines
KR100399361B1 (en) * 1999-11-04 2003-09-26 주식회사 엘지생명과학 Therapeutic composition comprising caspase inhibitor
EP1474121B1 (en) 2001-05-30 2010-07-21 The Regents Of The University Of Michigan Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
FR2840807B1 (en) 2002-06-12 2005-03-11 COSMETIC CARE AND / OR MAKEUP COMPOSITION, STRUCTURED BY SILICONE POLYMERS AND ORGANOGELATORS, IN RIGID FORM
WO2006009907A2 (en) * 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Isoxazolidine compounds for treatment of bacterial infections
WO2006009869A1 (en) 2004-06-17 2006-01-26 Infinity Pharmaceuticals, Inc. Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners
TWI403320B (en) * 2005-12-16 2013-08-01 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners

Also Published As

Publication number Publication date
KR20090082284A (en) 2009-07-29
NZ577243A (en) 2011-12-22
RU2009121808A (en) 2010-12-20
MX2009005184A (en) 2009-10-12
AU2007319848B2 (en) 2012-05-03
CN101583606B (en) 2015-04-08
JP2010510214A (en) 2010-04-02
BRPI0718606A2 (en) 2013-12-17
US7842815B2 (en) 2010-11-30
US8461191B2 (en) 2013-06-11
CA2669596A1 (en) 2008-05-22
GT200900123A (en) 2011-09-02
RU2449996C2 (en) 2012-05-10
CA2669596C (en) 2014-09-30
MY156754A (en) 2016-03-31
HK1130057A1 (en) 2009-12-18
AU2007319848A1 (en) 2008-05-22
EP2094673B1 (en) 2015-04-08
CN101583606A (en) 2009-11-18
JP2014055156A (en) 2014-03-27
WO2008060569A1 (en) 2008-05-22
ECSP099398A (en) 2009-07-31
IL198597A (en) 2014-03-31
NO20092306L (en) 2009-08-17
US20110160259A1 (en) 2011-06-30
EP2094673A1 (en) 2009-09-02
KR101530721B1 (en) 2015-06-22
IL198597A0 (en) 2010-02-17
US20080306127A9 (en) 2008-12-11
TN2009000182A1 (en) 2010-10-18
ES2537762T3 (en) 2015-06-11
US20070161690A1 (en) 2007-07-12

Similar Documents

Publication Publication Date Title
MA31067B1 (en) COMPOUNDS AND METHODS FOR INHIBITING INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS.
MA30673B1 (en) COMPOUNDS AND METHODS FOR INHIBITING BCL PROTEIN INTERACTION WITH BINDING PARTNERS
MA30144B1 (en) COMPOUNDS AND METHODS FOR INHIBITING BCL PROTEIN INTERACTION WITH BINDING PARTNERS
IL179904A0 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MA31147B1 (en) 4-Phenyl-Piran-5.3-Dion, 4-Phenyl-Tuberan-5.3-Dion and Cyclohexatrion as new herbicides.
MX2009006307A (en) Iron (iii)-carbohydrate based phosphate adsorbent.
MA31304B1 (en) MOLECULES AND METHODS FOR PROPYTEIN CONVERTASE MODULATION SUBTILISINE / KEXINE TYPE 9 (PCSK9)
MA31821B1 (en) Humanized anti-cxcr5 antibodies, their derivatives and their uses
SG171682A1 (en) Iap bir domain binding compounds
NO20015417D0 (en) Treatment of autoimmune diseases with antagonists that bind to B cell surface markers
WO2005074633A3 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
MX2010004219A (en) Cd19 binding agents and uses thereof.
MX2010001565A (en) Triazole compounds that modulate hsp90 activity.
MA30988B1 (en) COMPOUNDS FOR INHIBITING MITOTIC PROGRESSION
WO2007094819A3 (en) Triazole compounds that modulate hsp90 activity
IN2014DN08588A (en)
MY148299A (en) Iron-carbohydrate complex compounds
MX2007004001A (en) Method for the treatment of polycystic kidney disease.
WO2007026251A3 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
WO2007022947A3 (en) 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
BRPI0508084A (en) method for the treatment of a neurological disorder, and use of meridamycin or a salt thereof
MY155908A (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
TW200730192A (en) Compositions for separation of a plurality of distinct targets from a sample
TW200621265A (en) Composition for treating tumor and/or preventing tumor transfer and recurrence